Is the treatment of high-risk SMM the way for achieving the cure?

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES, answered: Is the treatment of high-risk smoldering multiple myeloma (SMM) the way for achieving the cure?

In this presentation, Mateos discusses the progression of monoclonal gammopathy of undetermined significance (MGUS) and SMM to MM from a molecular point of view. She explains the 2/20/20 risk stratification model for SMM, and the phase III clinical trials that have demonstrated a benefit in treating patients with high-risk SMM to delay the progression to overt MM. In her road map to cure MM, early treatment of SMM is a crucial step, and she presents two curative approaches being currently investigated in clinical trials.

Find below links to the other talks from the symposium:

'Does 'cure' have a different meaning in MM?' presented by Mohamad Mohty.  

'Is transplantation still relevant? If yes, in which context?' presented by Sagar Lonial.

'Treating elderly and frail patients with MM: Cure versus disease control' presented by Vincent Rajkumar.

'Roundtable discussion' with María-Victoria Mateos, Mohamad Mohty, and Sagar Lonial.